English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

International audienceAbstractBoth commercially available fumagillin-based treatments for honey bees (Apis mellifera), Fumagilin-B® as well as Fumidil-B®, contain the reportedly genotoxic and tumorigenic compound dicyclohexylamine (DCH) as the counter ion in the fumagillin-DCH salt. The effect of DCH, purified fumagillin (containing no DCH), and the commercial formulation Fumagilin-B® (containing both fumagillin as well as DCH) on the mortality of caged Nosema ceranae-infected honey bees was investigated. A statistically significant risk of bee mortality associated with oral exposure to DCH was observed. DCH is also known to be significantly more stable than fumagillin in honey under a variety of temperature conditions, both in the presence and absence of light. The presence of DCH in the hive is therefore a potential concern for bee health and also for food safety

The effect of dicyclohexylamine and fumagillin on Nosema ceranae-infected honey bee (Apis mellifera) mortality in cage trial assays